Evaluating a new dengue vaccine in healthy participants.
A STUDY TO ASSESS EFFICACY, SAFTETY AND PHARMACOKINETICS OF EYU688 IN HEALTHY PARTICIPANTS CHALLENGED WITH DENGUE SEROTYPE 2
This study is looking for healthy people to try out a new dengue vaccine called EYU688 to see how well it works and if it’s safe, as they will be exposed to the dengue virus; by joining, you'll help in the effort to create a vaccine that could protect against dengue fever.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10925568 on NIH RePORTER |
What this research studies
This research investigates the safety and effectiveness of a new dengue vaccine candidate called EYU688 in healthy individuals who are intentionally exposed to Dengue virus serotype 2. Participants will receive the vaccine and then be monitored for their immune response and any side effects. The study aims to gather important data on how well the vaccine works and how it is processed in the body. By participating, individuals will contribute to the development of a potential vaccine that could protect against dengue fever.
Who could benefit from this research
Good fit: Ideal candidates for this research are healthy adults who are willing to participate in a clinical trial and are at risk of dengue virus exposure.
Not a fit: Patients with pre-existing health conditions or those who have previously been infected with dengue may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safe and effective vaccine for dengue fever, potentially reducing the incidence of this viral disease.
How similar studies have performed: Previous research on dengue vaccines has shown promise, indicating that this approach could lead to significant advancements in dengue prevention.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Durbin, Anna Palmer — Johns Hopkins University
- Study coordinator: Durbin, Anna Palmer
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.